From NIH grant caps to FY27 appropriations to a landmark biosecurity push, this week’s policy developments touch every corner of our ecosystem. A few things worth knowing.
NIH Floats Cap on Simultaneous Grants Per Investigator: On June 8, NIH released a Request for Information (NOT-OD-26-086) proposing to cap the number of Research Project Grants on which an individual can serve simultaneously as principal investigator. Comments on the proposal are due August 3, 2026. NIH introduced a similar proposal nearly a decade ago, but it was dropped after receiving swift and reaching backlash from the scientific community. This time around, the NIH is framing the idea as a way to spread funding to more investigators, weighing geographic balance alongside scientific merit. By NIH’s figures, a two-grant cap would redirect about $3.5 billion, or 13.3 percent of RPG funding, to roughly 5,230 additional investigators. Capping grants per investigator risks paring back larger, productive labs, and it could discourage the collaborations that enable complex biomedical science. We support broadening opportunities for early-stage investigators, but not by penalizing scale and productivity, and we will engage during the comment window to protect both scientific merit and the Massachusetts labs that drive discovery.
House Appropriations Advances FY27 Labor-HHS Bill with Biomedical Research Funding: On June 9, the full House Appropriations Committee approved its FY2027 Labor, Health and Human Services, Education, and Related Agencies bill by a party-line vote of 34 to 28. The bill provides a total discretionary allocation of $189.3 billion, down $5.6 billion, or 3 percent, from FY2026. Of that, $48.8 billion is directed to biomedical research, which the committee framed as a way to counter China’s growing influence in basic science, and another $105 million supports research, development, and procurement of medical countermeasures within the Administration for Strategic Preparedness and Response to strengthen U.S. biodefense. The funding picture across the rest of the bill is mixed. NIH received a modest increase of 1.5 percent and was the clearest piece of bipartisan support in the package. The CDC, by contrast, absorbs roughly $1 billion in aggregate cuts across its immunization, emerging disease, and HIV and AIDS accounts, with several programs folded into the broader agency structure. The bill also cuts roughly $2 billion from ACA marketplace operations, which would narrow access even for people who remain eligible for coverage. Committee approval is just the first step. The bill still needs to clear the full House, and the Senate must pass its own version, which will likely differ on funding levels and policy. The two chambers will then need to reconcile their differences later this year before any proposals become law.
FDA Issues Draft Guidance to Accelerate Cell and Gene Therapies: On June 2, the FDA released draft guidance, “Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing” (Docket FDA-2026-D-1257). The guidance outlines how sponsors can rely on existing scientific and regulatory knowledge, including publicly available data and established platform knowledge across chemistry, manufacturing and controls, nonclinical results, and clinical information, to streamline submissions for somatic genome-editing therapies rather than rebuilding the evidence base for each new product. Acting CBER leadership framed the move as speeding therapies for patients with rare and life-threatening diseases without lowering safety standards. Given Massachusetts’ role as a hub for early-stage biotech innovation, MassBio is excited to see FDA reducing barriers to clinical trials. The change should accelerate research and widen patient access while also reinforcing US competitiveness against China.
AI and Biosecurity Leaders Press Congress to Mandate DNA Synthesis Screening: In an open letter publicized the week of June 4, 69 artificial intelligence and national security leaders, including the chief executives of Anthropic, OpenAI, and Google DeepMind, urged Congress to make nucleic acid synthesis screening and recordkeeping mandatory. As AI and biotechnology converge and orders for synthetic DNA rise, the signatories argue that screening synthesis requests for sequences of concern and keeping records of individual orders is necessary to maintain biosecurity and deter misuse. The effort aligns with longstanding recommendations from the National Security Commission on Emerging Biotechnology and could lead to movement within the House and Senate biotech caucuses on biotech safety, though no bill text is yet tied to the letter. We support sensible biosecurity measures and will engage early to ensure any requirements are workable for small and emerging companies.
Next week: With the House in recess, the action shifts to the Senate, where we are tracking two hearings on Wednesday, June 17. At 10:00 AM, the Senate HELP Committee holds an executive session to mark up a full slate of health care bills. At 2:30 PM, the Senate Small Business Committee examines 250 years of small business on Main Street, where we will listen for how members frame the role of biotech and research in supporting small firms.